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OBJECTIVES This study was designed to determine predictors of restenosis after successful percutaneous
mitral commissurotomy (PMC) and its relationship to late clinical outcome.
BACKGROUND The restenosis rate after PMC and its relationship to late clinical outcome is poorly defined.
METHODS Serial echocardiography was performed in 310 patients who underwent PMC. Restenosis,
defined as mitral valve area (MVA) 1.5 cm2 and 50% loss of initial MVA increase, was
determined by both two-dimensional (2D) and Doppler echocardiography. Clinical, echo-
cardiographic and cardiac catheterization variables were evaluated to determine predictors of
restenosis. The relationship between restenosis and major adverse clinical events (death,
repeat PMC or mitral valve replacement) and functional status was assessed.
RESULTS Acute procedural success occurred in 206 patients (66%), who were then followed for
restenosis. The cumulative restenosis rate was approximately 40% at six years after successful
PMC (44% by 2D and 40% by Doppler MVA). The only independent predictor of restenosis
was echocardiographic score (restenosis at five years was 20% for score 8 vs. 61% for score
8, p  0.001). The decline in MVA and occurrence of restenosis was gradual and
progressive during the follow-up period. Procedural results and baseline factors predicted
event-free survival. Restenosis by 2D MVA was related to adverse events or New York Heart
Association functional class 3 to 4 symptoms, but restenosis was not an independent predictor
of clinical outcome by multivariate analysis.
CONCLUSIONS Restenosis is a common, gradual and progressive occurrence after successful PMC and is
predicted by higher echocardiographic score. Restenosis is related to late adverse clinical
outcome, though clinical outcome remains best predicted by the acute procedural results of
PMC. (J Am Coll Cardiol 2002;39:328–34) © 2002 by the American College of
Cardiology
Percutaneous mitral commissurotomy (PMC) using the
Inoue balloon is an effective treatment for patients with
mitral stenosis (MS) and suitable valve morphology. Reste-
nosis after PMC has been evaluated in a number of studies,
with an incidence ranging from 4% to 39% (1–6). This
variability reflects the different definitions of restenosis,
duration and consistency of follow-up and/or small cohorts
of patients in previous studies.
Furthermore, the relationship between restenosis and
long-term clinical outcome is not well defined. Iung et al.
(7) have recently reported that restenosis occurred in 97% of
patients with poor functional results (New York Heart
Association [NYHA] functional class III or IV symptoms)
after PMC. However, because restenosis was not evaluated
for the entire patient population, its relationship to func-
tional status is unclear. The objectives of this study were to:
1) determine the rate of restenosis by annual serial echocar-
diography after successful PMC; 2) determine the variables
related to restenosis; and 3) assess the relationship between
restenosis and long-term clinical outcome after successful
PMC.
METHODS
Study population. From 1990 to 1999, 310 consecutive
patients with symptomatic MS and mitral valve area (MVA)
1.5 cm2 underwent Inoue balloon (Toray Inc., Tokyo,
Japan) PMC at our institution. Informed consent was
obtained from all patients in accordance with a protocol
approved by the Institutional Review Board of Duke Uni-
versity Medical Center. Patients with mitral regurgitation
(MR) higher than Sellers grade 2 by left ventricular (LV)
angiography (8) or evidence of left atrial (LA) thrombus by
transesophageal echocardiography did not undergo PMC.
Baseline characteristics are depicted in Table 1.
Catheterization data and PMC procedure. The tech-
nique of Inoue balloon PMC (9) and our protocol of data
collection at the time of PMC (10) have previously been
described. Standard hemodynamic measurements of the
right and left heart, including simultaneous measurement of
LA and LV pressures, were made before and immediately
after the procedure using fluid-filled catheters. The trans-
mitral pressure gradient was determined by computerized
planimetry of the LA and LV diastolic pressure difference.
Cardiac output was determined by the Fick method and
MVA was calculated using the Gorlin and Gorlin formula,
with an empiric constant of 40 (11). The average diastolic
From the Department of Medicine, Duke University Medical Center, Durham,
North Carolina.
Manuscript received June 11, 2001; revised manuscript received September 4, 2001,
accepted October 18, 2001.
Journal of the American College of Cardiology Vol. 39, No. 2, 2002
© 2002 by the American College of Cardiology ISSN 0735-1097/02/$22.00
Published by Elsevier Science Inc. PII S0735-1097(01)01726-0
area of three beats was used for patients in sinus rhythm; the
average of 10 beats was used to calculate the Gorlin valve
area for patients in atrial fibrillation. After the procedure, a
right heart oximetry series was performed to evaluate for
residual left-to-right shunting after withdrawal of the bal-
loon catheter from the interatrial septum. When a left-to-
right shunt of 1.3 was observed (n  29, 9%), the
calculated systemic blood flow was substituted for the
cardiac output in the Gorlin formula. Biplane left ventricu-
lography was performed before and after the procedure and
MR severity was graded using the Sellers classification (8).
Clinical and echocardiographic follow-up. Clinical and
echocardiographic evaluations were performed immediately
before PMC, then 24 h, six months, one year and yearly
thereafter. Clinical assessment included a detailed history
and physical examination with determination of functional
status by NYHA functional class. Echocardiography was
performed at each interval by the same sonographer
(K. B. K.) before the clinical assessment. Two-dimensional
(2D) and Doppler echocardiographic examinations were
performed with a commercially available phased-array sec-
tor scanner with 2.5-MHz transducer (Hewlett-Packard,
Palo Alto, California). Mitral valve area was determined by
2D planimetry of the mitral valve orifice and by the Doppler
half-time method. Echocardiographic measurements of
MVA were not analyzed if the quality of the 2D image or
Doppler profile was considered technically inadequate. All
results were based on the average of three measurements for
patients in sinus rhythm and six measurements for patients
in atrial fibrillation. Mitral valve morphology was assessed
the day before PMC using a semiquantitative echocardio-
graphic score (0 to 4) for each of four valve characteristics:
leaflet mobility, thickening, calcification and subvalvular
thickening (12). The presence and severity of MR was
evaluated by using color flow Doppler imaging from the
parasternal long-axis and apical views. Mitral regurgitation
was graded from 0 to 4, depending on the spatial extent of
the color flow jet area expressed as a percentage of LA area
(13).
Clinical and echocardiographic follow-up was truncated
at the time of a major adverse clinical event, defined as
death, repeat PMC or mitral valve replacement. Restenosis
was primarily defined as MVA 1.5 cm2 and a 50% loss of
initial gain in MVA, using the pre- and post-PMC MVA
by the Gorlin formula as the reference value. For evaluating
restenosis, the subset of patients with successful PMC
results was studied. Successful PMC was defined as MVA
1.5 cm2 by Gorlin formula (11) and MR 2 by
angiography immediately after PMC. Because variability
between noninvasive and invasive measures of MVA has
been described both before and after PMC (10,14), reste-
nosis was evaluated by both 2D and Doppler methods
during follow-up. Various definitions of restenosis were
then explored for the prediction of major events or NYHA
functional class III or IV heart failure symptoms: MVA
1.5 cm2 and a 75% loss of initial gain in MVA, absolute
MVA and MVA as a proportion of immediate post-PMC
MVA.
Statistical analysis. Continuous data are reported as mean
 standard deviation and categorical variables as the num-
ber and percentage of patients. Differences in categorical
factors and procedural outcomes are compared using a
Pearson chi-square test. Differences in procedural outcomes
for continuous variables were compared using paired t test.
A p value 0.05 was considered statistically significant.
Univariable comparisons of baseline and preprocedural fac-
tors and postprocedural outcomes were made using Excel
97. All other statistical analyses were performed using SAS
Version 6.12 (SAS Institute, Cary, North Carolina).
Restenosis after successful PMC was assessed at six
months, one year and yearly thereafter. To determine
predictors of this binary outcome, a generalized linear model
was applied. This model assumed a binomial distribution
with a logit link function and applied repeated measures of
the data over time. Once a patient met the definition of
restenosis, restenosis was assumed for all subsequent
follow-up intervals at which data were collected on the
Abbreviations and Acronyms
LA  left atrial
LV  left ventricular
MR  mitral regurgitation
MS  mitral stenosis
MVA  mitral valve area
NYHA  New York Heart Association
PMC  percutaneous mitral commissurotomy
2D  two-dimensional
Table 1. Baseline Characteristics of the Study Population
Total
Population
(n  310)
Successful
PMC
(n  206)
Unsuccessful
PMC
(n  104)
Age, years 52  13 50  13 54  13*
Female gender 265 (85%) 170 (82%) 95 (91%)*
NYHA functional class
1 3 (1%) 2 (1%) 1 (1%)
2 82 (26%) 57 (28%) 25 (24%)
3 199 (64%) 134 (65%) 65 (63%)
4 26 (8%) 13 (6%) 13 (12%)
Atrial fibrillation 102 (33%) 61 (30%) 41 (39%)
Prior commissurotomy 52 (17%) 30 (14%) 22 (21%)
Mitral valve area, cm2 1.1  0.2 1.1  0.2 1.0  0.2
Mitral valve echo score
Mobility 2.2  0.7 2.1  0.7 2.4  0.7
Thickening 2.5  0.8 2.4  0.8 2.7  0.7
Calcification 2.6  0.8 2.5  0.8 2.8  0.7
Subvalvular thickening 1.5  0.8 1.5  0.7 1.7  0.9
Total score 8.8  2.3 8.5  2.2 9.5  2.3*
Mitral regurgitation
0 186 (60%) 137 (67%) 49 (48)*
1 97 (31%) 56 (27%) 41 (40%)
2 21 (7%) 10 (5%) 10 (10%)
*p  0.05 for comparison between successful and unsuccessful PMC.
NYHA  New York Heart Association; PMC  percutaneous mitral commis-
surotomy.
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patient. A backward selection technique was applied to
determine the set of baseline and postprocedural factors that
were multivariably predictive of restenosis.
Long-term event-free survival was estimated using a Cox
proportional hazards model. The assumption of propor-
tional hazards was evaluated and no factor greatly violated
this assumption. The association of this outcome with
baseline and postprocedural factors was evaluated using a
stepwise variable selection technique. The variables evalu-
ated were age, gender, NYHA functional class, previous
surgery, total echocardiographic score, atrial fibrillation;
preprocedural MVA, MR, mean atrial pressure, mitral
gradient and LA pressure and postprocedural MVA, MR,
mitral gradient and LA pressure. Forward stepwise variable
selection techniques were used on the baseline and prepro-
cedural variables and postprocedural variables separately.
The results of these two models were combined and forward
stepwise selection was again used to develop the final model.
The association between restenosis and long-term event-
free survival was tested using restenosis as a time-dependent
covariate. This was evaluated initially by univariate analysis
and subsequently by multivariate analysis including those
factors found to be associated with survival.
RESULTS
Procedural results. For the total patient population (n 
310), PMC resulted in an increase in MVA from 1.1 
0.2 cm2 to 1.7  0.5 cm2 (p  0.001) and a reduction in
mean transmitral gradient from 12.5 4.8 mm Hg to 6.8
3.3 mm Hg (p  0.001). The mean Sellers MR grade
increased from 0.5  0.6 to 0.9  1.0 (p  0.001) after
PMC.
Successful PMC, as defined above, was accomplished in
206 (66%) patients. For the patients with successful PMC,
mean MVA increased from 1.1  0.2 cm2 to 1.9  0.4 cm2
(p  0.001) and mean MR increased from Sellers grade
0.4  0.6 to 0.6  0.7 (p  0.001) after the procedure.
Percutaneous mitral commissurotomy was defined as unsuc-
cessful because of residual mitral stenosis (MVA 1.5 cm2)
in 77 (25%) patients and the presence of severe (3 or 4)
MR in 27 (9%) patients. Baseline characteristics of patients
who had successful PMC compared with unsuccessful PMC
are depicted in Table 1. In general, patients who had
successful PMC were younger (p 0.016), more often men
(p  0.020), had lower total echocardiographic score (p 
0.001) and had less angiographic MR before PMC (67%
with no baseline MR in the successful group compared with
48% in the unsuccessful group; p  0.002).
Event-free survival. The median follow-up duration for
the patient population was 3.3 years. There were 69 major
adverse clinical events in the entire cohort (11 deaths, 58
mitral valve replacement surgeries). Two of the 11 deaths
(18%) were cardiac. Within the group with successful PMC,
30 major events occurred during clinical follow-up: 2 deaths
(1 cardiac) and 28 mitral valve replacements (13 for pre-
dominant MS, 10 for predominant MR and 5 for combined
MS/MR). In the unsuccessful PMC group, 39 major events
occurred: 9 deaths and 30 mitral valve replacements (17 for
predominant MR, 10 for predominant MS and 3 for
combined MS/MR). The median time to major event after
successful PMC was 978 days (25th to 75th percentile, 455
to 1,727 days) compared with 62 days (25th to 75th
percentile, 10 to 329 days) after unsuccessful PMC. Event-
free survival for patients with successful PMC compared
with unsuccessful PMC is shown in Figure 1. Patients with
successful PMC had a three-year event-free survival of 88%
compared with 63% after unsuccessful PMC (five-year
event-free survival 81% vs. 54%, respectively).
For the total patient population, multivariable logistic
regression analysis demonstrated that the pre- and postpro-
cedural predictors of event-free survival were post-PMC
mitral gradient (X2  28.9, p  0.001), post-PMC MR
severity (X2  16.5, p  0.001) and prior surgical commis-
surotomy (X2  6.8, p  0.009). In the group who had a
successful PMC procedure, independent predictors of
event-free survival were post-PMC mitral gradient (X2 
7.2, p  0.007), post-PMC LA pressure (X2  6.2, p 
0.013) and echocardiographic score (X2  2.8, p  0.095).
When NYHA functional class III or IV symptoms was
considered a major end point, the multivariate model
yielded the following predictors: echocardiographic score
(X2  11.6, p  0.001), baseline NYHA functional class
(X2  11.4, p  0.001), post-PMC mitral gradient (X2 
7.8, p  0.005) and age (X2  7.1, p  0.007).
The relationship between echocardiographic restenosis
after successful PMC and clinical outcome was investigated
using unadjusted and adjusted 2D and Doppler MVA.
Although restenosis defined by Doppler MVA was not
related to clinical outcome, restenosis by 2D echocardiog-
raphy was found to be associated with time to major events
after successful PMC (X2  5.9, p  0.015) (Fig. 2).
Restenosis by 2D MVA was more strongly related to time
to major events or NYHA functional class III or IV
symptoms (X2  9.0, p  0.003) by univariable analysis.
However, when adjusted for pre- and post-PMC clinical,
echocardiographic and catheterization variables, neither
method independently predicted clinical outcome. Addi-
tionally, because the definition of restenosis may be some-
what arbitrary, three other criteria were investigated: MVA
1.5 cm2 and 75% loss of PMC gain, MVA as a
proportion of immediate post-PMC MVA, and absolute
MVA. However, none of these predicted major events or
functional class III or IV symptoms after adjustment for
pre- and post-PMC variables.
Echocardiographic follow-up and restenosis. Among the
subset of patients with successful PMC, 25 of 206 (12%) did
not have an echocardiographic measurement of MVA by
either 2D or Doppler methods during follow-up. In addi-
tion, 22 patients (11%) did not have adequate 2D measure-
ment of MVA.
After successful PMC, MVA as measured by 2D echo-
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cardiography (planimetry) decreased by an average of
0.08 cm2/year. Mitral valve area by Doppler echocardiog-
raphy decreased by an average of 0.06 cm2/year. Compari-
son between the two echocardiographic methods after PMC
demonstrated a progressive, gradual decrease in MVA over
time with both 2D and Doppler measurements. Likewise,
the percentage of patients who met the definition of
restenosis was similar and progressive for both MVA
measures over time (approximately 6% to 7% per year).
Thus, at six-year follow-up, approximately 40% of patients
had evidence of echocardiographic restenosis by either 2D
or Doppler MVA. During the follow-up period, the distri-
bution of MR severity did not change after successful PMC.
Multivariable logistic regression analysis was performed
to determine predictors of restenosis after successful PMC
using the following variables: age, gender, baseline func-
tional status, prior commissurotomy, cardiac rhythm, echo-
cardiographic score, MVA (pre-PMC), mitral gradient
(pre-PMC), MR (pre-PMC), mean pulmonary artery
pressure (pre-PMC), MVA (post-PMC), mitral gradient
(post-PMC) and MR (post-PMC). Only echocardio-
graphic score was found to predict restenosis (z  3.42;
p  0.001). Restenosis as a function of echocardiographic
score is depicted in Figure 3. Patients with a baseline
echocardiographic score 8 (n  73) had a five-year
restenosis rate of 20% compared with 61% for those with
total score 8.
DISCUSSION
In the present study, serial echocardiography was performed
in a large, consecutive cohort of patients undergoing Inoue
balloon PMC in order to define the incidence and clinical
implications of restenosis. The results demonstrate that
after successful PMC, restenosis was: 1) a gradual and
progressive process during long-term follow-up; 2) pre-
dicted only by baseline echocardiographic score; and 3)
related to poorer long-term outcome but less important than
acute procedural results and baseline variables for predicting
event-free survival. To our knowledge, this is the largest
North American cohort of patients undergoing PMC and
followed by serial clinical and echocardiographic evaluations
in order to define the clinical implications of restenosis. This
study is unique in its evaluation of mitral valve restenosis in
relation to baseline and postprocedural variables.
Restenosis after PMC. Restenosis after PMC has been
evaluated in prior studies, but the reported rates have been
quite variable. This variability is related to multiple factors,
including different definitions of restenosis, durations of
follow-up, techniques for measuring MVA and methods of
sampling within a given cohort of patients.
The definition of restenosis in the present study was that
most widely used in the literature (2–4,6). This definition
(MVA 1.5 cm2 and 50% loss of initial gain in MVA)
thereby limits the assessment of restenosis to the subgroup
Figure 1. Event-free survival and procedural success. PMC  percutaneous mitral commissurotomy.
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of patients who have had successful PMC results (specifi-
cally, post-PMC MVA 1.5 cm2). Because procedural
results have been found to be the strongest predictor of
event-free survival in the present and prior studies (6,15),
the issue of restenosis is less clinically relevant for those
patients who do not meet this definition of acute procedural
success. Indeed, clinical follow-up of the subset of patients
with unsuccessful PMC results demonstrated a high rate of
adverse events within the first year, as a consequence of
severe mitral regurgitation or inadequate relief of mitral
stenosis. On the other hand, the issue of restenosis is a
common clinical consideration in the follow-up of patients
after successful PMC.
Changes in MVA and restenosis rates in this study were
similar and consistent for both 2D and Doppler echocar-
diographic measures of MVA. Using either measure of
MVA, restenosis occurred in approximately 40% of patients
six years after successful PMC. Although this percentage
may seem high, Hernandez et al. (6) reported a similar rate
of restenosis (39% at seven years) in their European cohort.
In the present study, only total echocardiographic score at
baseline was found to predict restenosis. Although initially
developed to assess the morphology of mitral valve as a
predictor of procedural success (12), the echocardiographic
score has recently been associated with restenosis as well
(6,16). Calcification of the mitral valve, either leaflet or
commissure involvement, has also been related to restenosis
(4,17). Finally, in a study of 103 patients with mild MS who
did not undergo PMC, Sagie et al. (18) found that the
baseline echocardiographic score was a weak predictor of the
rate of progression of MS. This association between the
echocardiographic score and progression of MS or resteno-
sis remains unexplained. One possibility is that higher
echocardiographic score may reflect ongoing rheumatic
involvement or an immunologic response with progressive
valve injury. The gradual, progressive decline in MVA after
PMC and lack of relationship between immediate post-
PMC MVA and restenosis suggest that restenosis is an
ongoing biological process and not simply a mechanical or
“recoil” phenomenon.
Restenosis and clinical outcome. Our study demonstrated
that restenosis defined by 2D echocardiographic measure-
ment of MVA was related to late clinical outcome. How-
ever, this relationship between restenosis by 2D MVA and
late clinical outcome was statistically weak. Although MVA
continues to decline during long-term follow-up, event-free
survival was excellent after successful PMC (81% at five
years), demonstrating the disparity between the gradual
process of restenosis and clinical outcome. The acute pro-
cedural results of PMC were the predominant predictors of
event-free survival for both the entire cohort and the
subgroup of patients with successful PMC. Thus, whereas
univariable regression analysis found that restenosis defined
by 2D MVA was associated with major adverse clinical
events or impaired functional status, when adjusted for
baseline factors and postprocedural results, restenosis was no
Figure 2. Event-free survival after successful percutaneous mitral commissurotomy as a function of restenosis by two-dimensional echocardiography.
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longer predictive of either major events or poorer functional
status.
The disparity between restenosis and clinical outcome
suggests that the hemodynamic benefits of successful PMC
persisted beyond the point of restenosis as defined by this
study. A greater reduction in MVA or duration of time may
be necessary before recurrent symptoms develop. After
PMC, LA stiffness has been shown to decline significantly
(19), and this improvement in compliance may confer
symptomatic benefit despite a reduction in MVA. In sup-
port of this hemodynamic change after PMC, our multi-
variate analysis found that LA pressure after successful
PMC was an independent predictor of poor long-term
clinical outcome. Alternatively, variability between measures
of MVA may contribute to a higher perceived rate of
restenosis (10,14), yet the rates of MVA decline and
restenosis for both 2D and Doppler measures of MVA were
remarkably similar. Longer clinical follow-up of the patients
who experience restenosis may reveal a stronger association
between restenosis and adverse clinical events and poor
functional status.
This lack of association between restenosis and outcome
also supports current guidelines for repeat echocardiography
after successful PMC. The American Heart Association/
American College of Cardiology Guidelines for the Man-
agement of Patients with Valvular Heart Disease state that
after successful PMC, management of patients is similar to
that of asymptomatic patients with mitral stenosis (20).
Echocardiography is recommended initially after PMC to
determine the effect or complications of the procedure, but
thereafter only for patients with recurrent or worsening
symptoms (20). Closer clinical follow-up of patients with
echocardiographic scores 8 may be warranted after suc-
cessful PMC because the restenosis rate is particularly high
among these patients.
Study limitations. The immediate postprocedural MVA
determined by Gorlin formula was used as the reference
MVA for determination of restenosis. This measure was
chosen because of the recognized inaccuracy of the Doppler
MVA acutely after PMC (21). However, we have also
separately evaluated restenosis and MVA decline using
post-PMC 2D MVA as the reference MVA and found
similar results to those reported above. Selection bias may
have affected the clinical event rate during follow-up,
because criteria to proceed with mitral valve replacement
were clinically determined and not prespecified in the study.
However, because restenosis by echocardiography did not
independently predict time to clinical events or poor func-
tional status, it is unlikely that surgery was performed
primarily on the basis of the echocardiographic results.
Conclusions. Serial yearly echocardiographic assessment
following PMC demonstrates that restenosis of the mitral
valve is a common, gradual and progressive occurrence
whereas the severity of MR does not change substantially.
Figure 3. Freedom from restenosis by two-dimensional echocardiography after successful percutaneous mitral commissurotomy as a function of baseline
echocardiographic score.
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Patients with lower baseline echocardiographic scores are
less likely to experience restenosis. Although restenosis by
2D echocardiography is related to late adverse events after
successful PMC, a disparity exists between echocardio-
graphic restenosis and clinical outcome. The acute proce-
dural results of PMC remain the strongest predictors of
long-term clinical outcome.
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